Skip to content

Comparison Centre

Two compounds, the same questions, no cherry-picking

Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.

Sharing keeps the two compounds you picked.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

Melanotan II

A synthetic melanocortin peptide sold for tanning — unapproved everywhere, and routinely confused with genuinely approved melanocortin medicines.

L2Animal / lab studiesResearch / unapproved supply
Full profile

Afamelanotide

An approved melanocortin implant for a rare light-sensitivity disease — not a tanning drug, whatever the internet says.

L5Repeated human trialsApproved for a specific indication · FDA (US)
Full profile

How far human research has progressed

Melanotan II

Limited early human study; no approved development programme

Afamelanotide

Approved orphan medicine with completed pivotal trials

Claim-specific benefit evidence

A human exposure study or trial registration does not establish that the claimed benefit occurs.

Melanotan II

Not separately assessed; see the full profile.

Afamelanotide

Not separately assessed; see the full profile.

Human research context

Melanotan II

Limited early human study; no approved development programme

Afamelanotide

Approved orphan medicine with completed pivotal trials

Human efficacy evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Melanotan II

Strength of the human efficacy evidence15 of 100 evidence strength

Afamelanotide

Strength of the human efficacy evidence78 of 100 evidence strength

Preclinical (animal / lab) evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

Melanotan II

Strength of the animal and lab evidence55 of 100 evidence strength

Afamelanotide

Strength of the animal and lab evidence70 of 100 evidence strength

Human safety evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

Melanotan II

Strength of the human safety evidence10 of 100 evidence strength

Afamelanotide

Strength of the human safety evidence75 of 100 evidence strength

Regulatory status (legal position, not proof it works)

Melanotan II

Check jurisdiction-specific details in the profile.

Not an approved medicine in any major region and identified by FDA as a bulk substance presenting significant safety risks for compounding. It must not be confused with the approved melanocortin medicines bremelanotide, afamelanotide and setmelanotide, each of which has its own narrow, specific indication.

Afamelanotide

Named regulators: FDA (US)

FDA-approved (Scenesse) for increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare genetic disorder of severe light sensitivity. Approval is specific to that orphan indication.

Common claims

Melanotan II

  • · Tans the skin without sun exposure
  • · Suppresses appetite
  • · Increases libido

Afamelanotide

  • · Increases pain-free light exposure in EPP
  • · Confused online with unapproved 'melanotan' tanning products

How settled our evidence rating is

Melanotan II

Very low confidence in ratingL2Animal / lab studies

Afamelanotide

High confidence in ratingL5Repeated human trials

Cancer-related questions raised by the biology

These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.

Melanotan II

A recurring concern is that stimulating melanocytes could interact with melanoma risk. No human data demonstrate that Melanotan II causes cancer — and none establish it is safe in that respect. Unstudied is not reassuring.

Afamelanotide

Because it stimulates melanocytes, melanoma surveillance is part of its clinical monitoring. That is a monitored precaution, not a demonstrated cancer risk.

What this adds up to, in plain English

Melanotan II

The interesting work is in animals and lab studies. Treating it as an established human treatment is not supported by evidence.

Afamelanotide

Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.

A comparison is not a recommendation

Neither column here is an endorsement, and the compound with the higher numbers is not the “better” or “safer” one — it is simply the one with more or better-quality research behind it. Two compounds can both be poorly evidenced, and better-evidenced says nothing about whether either is a sensible idea for a specific person. That is a conversation for a qualified clinician.